JP2005539067A5 - - Google Patents

Download PDF

Info

Publication number
JP2005539067A5
JP2005539067A5 JP2004536556A JP2004536556A JP2005539067A5 JP 2005539067 A5 JP2005539067 A5 JP 2005539067A5 JP 2004536556 A JP2004536556 A JP 2004536556A JP 2004536556 A JP2004536556 A JP 2004536556A JP 2005539067 A5 JP2005539067 A5 JP 2005539067A5
Authority
JP
Japan
Prior art keywords
peg
binding moiety
antibody
recognition binding
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004536556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005539067A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/029059 external-priority patent/WO2004024889A2/en
Publication of JP2005539067A publication Critical patent/JP2005539067A/ja
Publication of JP2005539067A5 publication Critical patent/JP2005539067A5/ja
Withdrawn legal-status Critical Current

Links

JP2004536556A 2002-09-16 2003-09-16 ポリエチレングリコールリンカーを用いる二重特異性分子の産生 Withdrawn JP2005539067A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41173102P 2002-09-16 2002-09-16
PCT/US2003/029059 WO2004024889A2 (en) 2002-09-16 2003-09-16 Production of bispecific molecules using polyethylene glycol linkers

Publications (2)

Publication Number Publication Date
JP2005539067A JP2005539067A (ja) 2005-12-22
JP2005539067A5 true JP2005539067A5 (enExample) 2006-11-02

Family

ID=31994266

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004536556A Withdrawn JP2005539067A (ja) 2002-09-16 2003-09-16 ポリエチレングリコールリンカーを用いる二重特異性分子の産生

Country Status (6)

Country Link
US (1) US20060153839A1 (enExample)
EP (1) EP1539811A4 (enExample)
JP (1) JP2005539067A (enExample)
AU (1) AU2003270686A1 (enExample)
CA (1) CA2499075A1 (enExample)
WO (1) WO2004024889A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002075275A2 (en) * 2001-03-15 2002-09-26 Elusys Therapeutics, Inc. Polyclonal populations of bispecific molecules and methods of production and uses thereof
AU2003247330B2 (en) * 2002-02-15 2008-06-12 Cygene, Inc. Methods and compositions for in vivo clearance of pathogens
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20060147457A1 (en) * 2002-05-13 2006-07-06 Porter James P Purified composition of bispecific molecules and methods of production
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2004087759A2 (en) * 2003-03-28 2004-10-14 Elusys Therapeutics, Inc. Method and compositions for conversion of antibody activity
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US20090036327A1 (en) * 2003-07-08 2009-02-05 Trex Enterprises Corp. Method for chemical treatment of porous silicon surface
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
AU2004282984B2 (en) * 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
WO2006050291A1 (en) * 2004-10-29 2006-05-11 Elusys Therapeutics, Inc. Use of cr1-binding molecules in clearance and induction of immune responses
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20060134694A1 (en) * 2004-12-22 2006-06-22 Intel Corporation Methods of protein profiling by thiolation
EP3144675A1 (en) * 2005-04-28 2017-03-22 Ventana Medical Systems, Inc. Enzymes conjugated to antibodies via a peg heterobifuctional linker
WO2006116742A2 (en) * 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Fluorescent nanoparticles conjugated to antibodies via a peg linker
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
DK1951316T3 (en) * 2005-11-23 2015-08-31 Ventana Med Syst Inc molecular conjugate
EP1968643A2 (en) * 2005-12-16 2008-09-17 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids into a cell
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
DE102006011507A1 (de) 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
US7935345B2 (en) 2007-05-21 2011-05-03 Children's Hospital & Research Center At Oakland Monoclonal antibodies that specifically bind to and neutralize bacillus anthracis toxin, compositions, and methods of use
WO2009048494A1 (en) * 2007-07-30 2009-04-16 Trex Enterprises Corporation Method of chemical treatment of porous silicon surfaces
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc Fc variants with altered binding to fcrn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
JP6415979B2 (ja) * 2011-06-03 2018-10-31 スリーエム イノベイティブ プロパティズ カンパニー ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
US9239332B2 (en) 2011-07-11 2016-01-19 Indi Molecular, Inc. Akt-specific capture agents, compositions, and methods of using and making
EP2784080B1 (en) * 2011-10-31 2019-12-18 Shimadzu Corporation Peptide-hinge-free flexible antibody-like molecule
MX349035B (es) * 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
WO2014033540A2 (en) * 2012-08-28 2014-03-06 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9913875B2 (en) 2015-03-16 2018-03-13 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
ES3017796T3 (en) * 2015-07-15 2025-05-13 California Inst Of Techn Il-17f-specific capture agents and methods of using
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
EP3638687A1 (en) 2017-06-15 2020-04-22 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
US12216122B2 (en) 2019-05-20 2025-02-04 Regeneron Pharmaceuticals, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (IDO1)
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
CN111557902A (zh) * 2020-07-03 2020-08-21 中国人民解放军总医院 一种负载阿仑膦酸钠的可注射聚乙二醇水凝胶的制备方法与应用
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
KR20250075704A (ko) 2022-09-30 2025-05-28 익스텐드 바이오사이언시즈, 인크. 장기-지속형 부갑상선 호르몬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4672044A (en) * 1984-08-24 1987-06-09 Scripps Clinic & Research Foundation Murine monoclonal antibody combining site to human C3b receptor (CR1)
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1992005801A1 (en) * 1990-10-04 1992-04-16 University Of Virginia Alumni Patents Foundation Primate erythrocyte bound monoclonal antibody heteropolymers
WO1992016221A1 (en) * 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5914112A (en) * 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
US6432679B1 (en) * 1998-06-12 2002-08-13 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
CA2405961A1 (en) * 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
WO2002046208A2 (en) * 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US20040018203A1 (en) * 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
WO2003049684A2 (en) * 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs

Similar Documents

Publication Publication Date Title
JP2005539067A5 (enExample)
US20240182542A1 (en) Multi-Specific Molecules
JP7076152B2 (ja) ＩｇＧ結合ペプチドによる抗体の特異的修飾
CN101616691B (zh) 多聚体缀合物
King et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments
Liu et al. Immobilized antibody orientation analysis using secondary ion mass spectrometry and fluorescence imaging of affinity-generated patterns
Lee et al. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds
Natarajan et al. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals
Renberg et al. Affibody molecules in protein capture microarrays: evaluation of multidomain ligands and different detection formats
JP2021504711A (ja) 標的による干渉が抑制された抗薬物抗体アッセイ
JP2005539067A (ja) ポリエチレングリコールリンカーを用いる二重特異性分子の産生
JP2019511201A5 (enExample)
JP6865584B2 (ja) 化合物の共有結合性コンジュゲーションのためのｍＴＧ基質
JP2022069446A5 (enExample)
JP2011506943A (ja) 識別アッセイ
CN1768266A (zh) 纯化稳定的放射性碘偶联物的方法
US20020197694A1 (en) Conjugates of reduced antibodies and biomolecules
Siemers et al. Construction, expression, and activities of L49-sFv-β-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation
Kikuchi et al. Determination of concentration and binding affinity of antibody fragments by use of surface plasmon resonance
Zhao et al. Site-specific modification of a single-chain antibody using a novel glyoxylyl-based labeling reagent
JP2005535898A (ja) 表面官能化のための方法及び試薬
Jones et al. Synthesis of LJP 993, a multivalent conjugate of the N-terminal domain of β2GPI and suppression of an anti-β2GPI immune response
Wade et al. Use of thiazolidine-mediated ligation for site specific biotinylation of mouse EGF for biosensor immobilisation
US11421083B2 (en) PETx polymer, preparation method and three-dimensional thorn-like sensor interface
Tai et al. Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers